retatrutide phase 2 trial results obesity of a new medication, Retatrutide, showed the highest amount of weight loss in a clinical so far. 24% of body weight lost. An average of 58 pounds over 48 weeks! The medical management of retatrutide weight loss phase 2

Limitations: - CT-388 data is early stage (Phase 1/2), making comparisons to late-stage or approved competitors regarding efficacy somewhat premature.- Competitor trials involving semaglutide and tirzepatide are based on larger patient populations and longer duration, providing a more robust data set validating their therapeutic benefit.- Weight loss achieved with GLP-1 receptor agonists such as semaglutide and the dual GLP-1/GIP receptor agonist tirzepatide appear greater than the weight loss observed to date with CT-388.- Competitor agents have established cardiovascular benefits and substantial net weight reductions, which set a high efficacy bar for CT-388 to meet or exceed.- Incretin therapies are challenged by supply shortages and complex titration schemes

GLP-1 drugs for obesity can impact health equity

kh2201059) and the Scientific research project of Health Commission of Hunan Province (No

More on this story Published2 July 2018 Published1 February 2019 Published7 July 2018 Published6 October 2017 Published6 April 2015 Published8 April 2011